Navigation Links
Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of data from a preclinical study of novel monoclonal antibodies against the cell-surface protein NTB-A. The data demonstrate that NTB-A is a potential new target for immunotherapy of B-cell malignancies including leukemia and lymphomas. The study, entitled "The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukemia and lymphoma therapeutics," appears in the May issue of British Journal of Haematology.

Leukemia and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become resistant to existing therapies.

"The development of new antibody therapeutics is an important area of study as leukemia and lymphoma patients need more treatment options. This study not only lays the scientific foundation for continued NTB-A target and antibody development, but it also validates the focus of our cancer antibody research and moves us closer to identifying a lead candidate from this program," said Walter Funk, Ph.D., vice president of research for Nuvelo. "In addition to pursuing the NTB-A target, we are also studying other monoclonal antibody targets in blood cell malignancies and solid tumor cancers, and have established collaborations with leading clinical centers that support our ongoing preclinical program."

NTB-A is a CD2-related cell surface protein expressed primarily on lymphoid cells including B-lymphocytes from chronic lymphocytic leukemia (CLL) and lymphoma patients. Nuvelo has generated a series of monoclonal antibodies against NTB-A and assessed their therapeutic potential for treating CLL and lymphoma through preclinical tri
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/21/2014)... 2014 UBM Medica US announces that ... community for primary care clinicians offers a photo collection ... victims of a variety of summer scourges.  ... a host of medical menaces: poison ivy, tick-borne infections, ... the highlights covered on Consultantlive,s topic center that includes ...
(Date:7/21/2014)... 2014 By order of the U.S. Bankruptcy Court, ... of ophthalmic and optical equipment, designer eyeglass frames, and other ... American Optical Services LLC. Online bidding opens July ... succession, live auction style, on July 28 beginning at 10:30 ... be held July 25 th and 26 th ...
(Date:7/21/2014)... Israel , July 21, 2014 Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, announced today that it ... July 25, 2014 to discuss results for the period ... on current developments with respect to its clinical program ...
Breaking Medicine Technology:ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3Auction Set For Assets Of National Optical Services Company 2Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2
... (NYSE Euronext Paris: COX) today announced that the ... with OA of the hip showed a highly,statistically ... of the trial. Naproxcinod 750 mg bid showed ... similar blood pressure profile,to placebo. Naproxcinod is the ...
... Nov. 21 Millions of Americans with moderate to severe ... new treatment option. Today, Johnson & Johnson Pharmaceutical Research ... Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief ... of age or older. , , ...
Cached Medicine Technology:Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 3Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 4Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
(Date:7/22/2014)... CT (PRWEB) July 22, 2014 ... to meet new Department of Transportation regulations: all ... examiners for the US Department of Transportation (DOT). ... the road, the DOT enforces strict standards to ... to operate limousines, taxis, trucks, and other commercial ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 ... provider of enterprise Time and Attendance / Workforce ... Iowa, a NOVAtime 3000 customer since 2007, has ... licensed version of NOVAtime’s state-of-the-art, web-based time and ... Services in Iowa (LSI) is a human services ...
(Date:7/22/2014)... Most people encounter the same two problems when trying to ... is a fast metabolism. These are hard problems to counteract on ... help fight these problems and to finally gain weight. , The ... who just can’t seem to eat more than a couple bites ... cause of this problem can vary. For some it can be ...
(Date:7/21/2014)... and kill cancer cells could boost the effectiveness of ... amputation, a new study reports. , Scientists at The ... a genetically engineered version of the virus used to ... virus alongside isolated limb perfusion chemotherapy given directly ... as an alternative to amputation was more effective ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 iFitDress.com, a ... for women, has announced its exclusive collection of 2014 ... launched a promotion for its brand new gowns. , ... in the current market. Its sales boomed in the ... elegant products, but also because of the amicable services ...
Breaking Medicine News(10 mins):Health News:PhysicianOne Urgent Care Physicians Become Certified Medical Examiners for DOT Physicals 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2
... appropriate care and treatment for a disease “Haemophilia” that ... a defect in the genes the World Haemophilia Day ... incurable genetic disorder that is characterised by a deficiency ... usually affects ,males. ,India has some 1,00,000 patients ...
... Bengal, who gave birth to a baby in a public street ... a call for probes here Tuesday. // ,Bengali news ... village in Birbhum district, about 180 km from here, lying on ... leave a hospital in Siuri town. ,The district ...
... has revealed that at least a third of dentists are refusing ... opposite to what Prime Minister Tony Blair had said when he ... ,"The majority of the dentists are agreeing to the new contract, ... however, that I think around about 90 to 95 per cent ...
... results that 43 percent of older people with diabetes ... //This is when these two damages are most common ... been recommended by national diabetes-treatment guidelines for years hardly ... evidence that they can prevent heart attacks, strokes, kidney ...
... Well known food brands hold many families sway to their ... the garb of promoting healthy food culture. // This attitude ... that are unable able to digest the ingredients, labeling and ... ,Is that what brand building is all about? Adopting a ...
... 25,000 affected in a malaria epidemic in Assam, officials Tuesday said. ... preventive steps and cure those hit by the disease," Assam Health ... people had died of cerebral malaria since the beginning of April, ... hit. ,"We have been able to check the spread ...
Cached Medicine News:Health News:Beware Of A Silent Killer Called Haemophilia 2Health News:Older Diabetics not taking kidney and heart protective drugs 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: